Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
PLWH in Romania Need More Comprehensive Care, Advocate Says
Nicoleta Dascalu, founding member and advocacy manager of Asociaţia Română Anti-SIDA (ARAS; Romanian Association Against AIDS), discusses the status of care for persons living with HIV/AIDS (PLWH) in Romania, including health care coverage and lack of adequate medication access.
Real-Time CGM Can Help Shape Patient Education, Glycemic Index Measures in T2D
Investigators from Malaysia utilized data from real-time continuous glucose monitoring (CGM) among study participants who were considered overweight or obese to evaluate their risk of type 2 diabetes (T2D) associated with a rice-based meal and its impact on postprandial hyperglycemia.
Dr Jason Myers Discusses How New Zealand Pivoted to Continue HIV Care During the Pandemic
Jason Myers, PhD, CEO of the New Zealand AIDS Foundation, addresses how New Zealand promptly adjusted its delivery of services for people living with HIV and AIDS in New Zealand, with examples including HIV self-test kits, online counseling, and provision of mental health care assistance.
CLS Use Proved Superior at Reducing Adverse Outcomes in T1D vs Control Therapies
This systematic review and meta-analysis used a literature search to gather data from long-term randomized controlled trials on the effectiveness of closed-loop insulin systems (CLS) among nonpregnant patients with type 1 diabetes (T1D).
NT-proBNP Level May Influence HF Risk Among Blacks vs Whites, Men vs Women
In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, prompted by growing interest in its use as a predictive biomarker for HF.
USPSTF Updates Preventive Aspirin Use Recommendation in CVD, CRC
There may be a small, but not overwhelming, benefit for certain individuals aged 40 to 59 years who have a slightly elevated risk of future cardiovascular disease (CVD) to start taking aspirin, according to an update released by the US Preventive Services Task Force (USPSTF).
Use of CSII Linked to Lower Rates of DEB Among Children With T1D
This new study investigated and compared the incidence of disordered eating behavior (DEB) among 2 cohorts of patients with type 1 diabetes (T1D) treated with continuous-subcutaneous insulin infusion (CSII) or a basal-bolus regimen.
Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography
This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.
Model Algorithm Demonstrates Effectiveness for T1D Control During Pregnancy
Investigators fashioned a zone-model predictive controller to evaluate adjustment of closed-loop glycemic control during pregnancy, as both glycemic control and insulin adjustment continually change throughout gestation.
Long-term Cardiac-Related Mortality Likely Predicted by 30-Day Postsurgical Outcomes
This study investigated long-term cardiac-related mortality as it relates to incidence of perioperative adverse cardiac events (excluding death) in the first 30 days after surgery among a short of patients who underwent non–cardiac-related surgery.
Dr Debra Patt Discusses Considering Strategies for Additional COVID-19 Boosters in Breast Cancer
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.
Choice of Breast Cancer Surgical Treatment Likely Influences Long-term QOL
This new study used data on women with stage 0 to II breast cancer to investigate their long-term quality of life (QOL) as it related to choice of surgery and the decision to undergo adjuvant radiation therapy.
Dr Roxana Siles: Multispecialty Management of Chronic Cough Maximizes Patient Benefits
Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the factors that contribute to necessitating multispecialty management of patients with chronic cough.
AstraZeneca’s Camille Hertzka Addresses rPFS in mCRPC
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.
Mixed QOL Findings Following Treatment Highlight Need for BC Support Services
This subanalysis of data from the ECOG-ACRIN E5103 trial evaluated longer-term quality of life (QOL) at the 18-month mark among patients with lymph node–positive or high-risk lymph node–negative breast cancer (BC) who have completed active treatment.
Medicare Must Address High ART Costs, Investigators Argue
With more people living with HIV now reaching advanced ages and qualifying for Medicare coverage, this new study investigated HIV-related influences on their health care spending, particularly antiretroviral therapy (ART), compared with a population who does not have HIV.
Morbidity, Mortality Improve in HFrEF With Combo Treatment vs Monotherapy
This new analysis of data from the Swedish Heart Failure Registry involved an investigation into the relationship between therapy count and dosing on mortality and morbidity among patients with heart failure with reduced ejection fraction (HFrEF).
AstraZeneca’s Camille Hertzka: Olaparib Could Be Practice Changing
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why so much excitement has been generated for the use of olaparib (Lynparza) in the first line for patients with metastatic castrate-resistant prostate cancer.
Coffee’s Preventive Benefits for CVD, Heart Disease on Display in Study Pair
Two studies presented at the annual meeting of the American College of Cardiology show the safety and effectiveness of regular coffee consumption in regard to cardiovascular disease and heart disease, as well as mortality.